PreciGenome, LLC develops CE-IVD certified FastPlex Triplex SARS-Cov-2 set of assays for the detection of the most prevalent COVID-19 mutations including UK B.1.1.7, Brazil P1, and South Africa B.1.351 variants.

PreciGenome, LLC develops CE-IVD certified FastPlex Triplex SARS-Cov-2 set of assays for the detection of the most prevalent COVID-19 mutations including UK B.1.1.7, Brazil P1, and South Africa B.1.351 variants.

United States, California, San Jose - 03/29/2021 — March 29, 2021 (San Jose, California) – PreciGenome, LLC (“PreciGenome”), a global leader in the development of innovative molecular diagnostic assays and instruments, has released the FastPlex Triplex SARS-Cov-2 set of assays for the detection of the most prevalent COVID-19 mutations including UK B.1.1.7, Brazil P1, and South Africa B.1.351 variants. The assays, which are compatible with industry leading PCR machines, have been CE-IVD approved for sale in Europe and are available in the US when designated as RUO.

The mutation suite is a collection of four separate assays that can be deployed either separately or sequentially depending on both instrument type and the specific sets of mutations a lab is attempting to determine.

  1. 02.01.1022 is a single test mutation assay which is optimized for 5-channel PCR that detects COVID-19 positive/negative and includes both H69-V70 and N501Y probes. This powerful single test confidently determines whether a patient is infected with COVID-19, the presence of UK variant, or whether another mutation may be present.
  2. 02.01.1044 is a 5-channel PCR test probing for H69-70Vdel, 242-244del, for UK 1.1.7 variant and E484K and K417N mutations for South Africa 1.351 variant, and N417T mutations for Brazil P1. It is designed to be run after our first test shows a patient is COVID-19 positive to hone in on a specific mutation.
  3. 02.01.1045 allows 6-channel PCR instruments to simultaneously test for COVID-19 positive/negative and the presence of the three most popular mutations. It includes H69-70Vdel, 242-244del and N501Y for UK 1.1.7 variant and E484K, K417N and N501Y mutations for South Africa 1.351 variant, E484K, N417T and N501Y mutations for Brazil P1 and N501Y for all 3 variants.

According to Brad Morgan, Chief Business Officer and Head of Business Development for PreciGenome: “These variants, especially UK B.1.1.7, have absolutely ravaged Europe and parts of the United States. Labs are looking for an efficient and reliable way to both retrospectively test stored samples and determine the presence of mutation in new patients. Variant testing is mandatory in many countries in Europe and the labs doing these tests simply do not have the right assays as their disposal. We therefore developed our mutation suite to meet the demands of current and future customers.”

About PreciGenome: Headquartered in San Jose with offices in Düsseldorf, Hong Kong, Suzhou, Delhi and Moscow, PreciGenome is an innovative medical technology company lead by an acclaimed team of Silicon Valley scientists dedicated to the transformation and application of microfluidics technologies to provide solutions for molecular biology.

Sales Inquiries:
Carman Kobza
Executive Vice President, Worldwide Sales
carman.kobza@precigenome.eu
info@precigenome.com
www.precigenome.com


Media Contacts:

Company Name: PreciGenome LLC
Full Name: Bradley Morgan
Phone: +1 4087084602
Email Address: Send Email
Website: www.precigenome.com